SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting
toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients
with Myelodysplastic Syndromes (MDS).
Phase:
Phase 1
Details
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborators:
H. Lee Moffitt Cancer Center and Research Institute National Heart, Lung, and Blood Institute (NHLBI)